| Ytd | -90.75% | |
| 1y | -99.45% |
| Open | 1.18 | Prev Close | 1.15 | Low | 1.18 | High | 1.24 | Mkt Cap | 2.82M |
| Vol | 22.89K | Avg Vol | 3.94M | EPS | -8.04 | P/E | -0.15 | Forward P/E | N/A |
| Beta | 3.52 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.53 | 200-d Avg | 8.22 | 1yr Est | 0.00 |
PPCB News
Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's
MELBOURNE, Australia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Pro
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 107.0% to $2.65 during Wednesday'
MELBOURNE, Australia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Pro
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceuti
MELBOURNE, Australia, July 21, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Pro
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's
MELBOURNE, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Pro
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's
MELBOURNE, Australia, July 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Pro
MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Pro
Friedman Industries Inc (NASDAQ: FRD) rose in pre-market trading after posting strong Q4 earnings. O
US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Indus
US stocks up, Dow gains 250 pts. Dow up 0.58% while NASDAQ up 0.67%. Materials shares jump 1.5%, com
MELBOURNE, Australia, June 11, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Pro
MELBOURNE, Australia, June 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Pro
MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Prop
MELBOURNE, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Prop
MELBOURNE, Australia, May 15, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Prop
MELBOURNE, Australia, May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Prop
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an inve
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an inve
The goal is to strengthen our intellectual property and to better understand how PRP technology can
MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Pr
The purpose of the study will be used as an important tool to measure the concentration of PRP and i
MELBOURNE, Australia, March 03, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Pr
We are pleased with advancements made with our R&D programs and